Investigational drug · Phase 3
TQC3721 for
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease, Pulmonary Disease, Chronic Obstructive.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
8
Any phase or sponsor naming "TQC3721 for"
First trial start
2024
Sep 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQC3721 for", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease
- Pulmonary Disease, Chronic Obstructive
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "TQC3721 for" as an intervention, largest first.
- Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07464587 · 800 participants (planned) · Start Apr 14, 2026 · Primary completion Feb 2027
Drug: TQC3721 Suspension for Inhalation · For: Chronic Obstructive Pulmonary Disease
Sites: Chizhou, China; Hefei, China; Chongqing, China · 54 sites in all
- Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07147946 · 666 participants (planned) · Start Sep 2025 · Primary completion Mar 2027
Drug: TQC3721 Suspension for inhalation; Placebo of TQC3721 Suspension for Inhalation · For: Chronic Obstructive Pulmonary Disease
Sites: Bozhou, China; Chizhou, China; Hefei, China · 76 sites in all
- A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06527144 · 240 participants · Start Sep 14, 2024 · Primary completion Jan 16, 2025
Drug: 3mg TQC3721 Suspension for Inhalation; 6mg TQC3721 Suspension for Inhalation and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Fuyang, China; Chongqing, China; Xiamen, China · 28 sites in all
- A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation PowderPivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07252908 · 195 participants · Start Dec 22, 2025 · Primary completion Apr 28, 2026
Drug: TQC3721 inhalation powder; Placebo for TQC3721 inhalation powder · For: Pulmonary Disease, Chronic Obstructive
Sites: Chongqing, China; Guangzhou, China; Jiangmen, China · 29 sites in all
- A Clinical Trial of TQC3721 Suspension for InhalationPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05051930 · 114 participants (planned) · Start Oct 18, 2021 · Primary completion Oct 31, 2022
Drug: TQC3721 suspension for inhalation; TQC3721 suspension placebo for inhalation · For: Chronic Obstructive Pulmonary Disease
Sites: Chengdu, China
- A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06748079 · 113 participants · Start Dec 3, 2024 · Primary completion Aug 7, 2026
Drug: TQC3721 inhalation powder; Placebo for TQC3721 inhalation powder and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Chengdu, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05987371 · 75 participants · Start Aug 23, 2023 · Primary completion Jan 16, 2024
Drug: TQC3721 suspension for inhalation; TQC3721 matching placebo for inhalation and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Guangzhou, China; Zhanjiang, China; Wuhan, China · 11 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05292196 · 59 participants · Start May 20, 2022 · Primary completion Jan 11, 2023
Drug: TQC3721 suspension for inhalation; TQC3721 suspension placebo for inhalation · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Chongqing, China; Lanzhou, China; Zhanjiang, China · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Obstructive Pulmonary Disease
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- CM326Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Moderate to Severe Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.